Healthcare / Medical DistributionHKSE
$0.32
-0.02 (-4.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-36.3M · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$138M
P/E
N/A
•EV/EBITDA
39.4x
↑ROE
-3.6%
↓Gross Margin
10.1%
↓Debt/Equity
0.85
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+16.5%
FCF CAGR
—
FCF margin
-7.1%
FCF / Net income
3.39x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $513.8M · net income $-10.7M · FCF $-36.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $513.8M | $513.8M | $552.3M | $498.0M | $324.6M |
| Net Income | $-10.7M | $-10.7M | $-53.0M | $14.6M | $15.8M |
| EBITDA | $9.3M | $9.3M | $-35.0M | $29.6M | $38.2M |
| EPS | — | — | -0.12 | 0.04 | 0.04 |
| Gross Margin | 10.1% | 10.1% | 10.2% | 15.7% | 27.7% |
| Operating Margin | 4.5% | 4.5% | 2.8% | 5.3% | 9.2% |
| Net Margin | -2.1% | -2.1% | -9.6% | 2.9% | 4.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.85 | 0.85 | 0.70 | 0.46 | 0.80 |
| Current Ratio | 1.65 | 1.65 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-36.3M | $-36.3M | $-183.9M | $171.6M | $-50.9M |
| Returns | |||||
| ROE | -3.6% | -3.6% | -17.7% | 4.7% | 5.2% |
| Valuation | |||||
| P/E | — | — | — | 46.70 | 44.81 |
| EV/EBITDA | 39.37 | 39.37 | — | 24.15 | 24.60 |
| P/B | 0.47 | 0.47 | 2.12 | 2.18 | 2.31 |
| Growth & Yield | |||||
| Revenue Growth | -7.0% | -7.0% | 10.9% | 53.4% | — |
| EPS Growth | — | — | -439.0% | -7.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-76.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.12 → n/d
Residual
-76.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.